Orchid gets nod for Granisetron generic formulation

19004 Investors following Orchid Chemical. Share this News with them.

0

Like this story, share it with millions of investors on M3

Orchid gets nod for Granisetron generic formulation

Chennai-based pharma major, Orchid Chemicals & Pharmaceuticals Ltd (Orchid) announced that it has received approval from the US FDA for its ANDA (Abbreviated New Drug Application) for Granisetron Hydrochloride Tablets. The product is available in 1 mg dosage strength.

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Orchid appoints Gopalan to head Drug Discovery initiative Orchid Chem net sales up by 39.4% to Rs 332.69cr Orchid Chemicals touches new high on good Q3 results ALSO READ See latest News about Orchid Chemical See previous management interviews See what other Experts & Brokerages are saying about Orchid Chemical Orchid Chemical BSE | NSE 25/05/12 Are Mutual Funds betting on Orchid Chemical?

Chennai-based pharma major, Orchid Chemicals & Pharmaceuticals Ltd (Orchid) today announced that it has received approval from the US FDA for its ANDA (Abbreviated New Drug Application) for Granisetron Hydrochloride Tablets. The product is available in 1 mg dosage strength.

An anti-emetic product, Granisetron is a new generation non-antibiotic product.

With limited generic competition, Orchid hopes to garner a strong market share leading to a sizeable revenue contribution from this product. 

Sourced From: Orchid Chemicals & Pharmaceuticals Ltd